BeiGene
BGNE
#881
Rank
S$28.88 B
Marketcap
$263.10
Share price
1.71%
Change (1 day)
-0.19%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total debt

Total debt on the balance sheet as of June 2024 : S$1.41 B

According to BeiGene 's latest financial reports the company's total debt is S$1.41 B. A companyโ€™s total debt is the sum of all current and non-current debts.

BeiGene - Total debt on balance sheet (from 2014 to 2024)

Total debt by year

Year Total debt Change
2023-12-31S$1.22 B53.58%
2022-12-31S$0.79 B-14.61%
2021-12-31S$0.93 B26.09%
2020-12-31S$0.74 B99.21%
2019-12-31S$0.37 B37.99%
2018-12-31S$0.27 B22.68%
2017-12-31S$0.22 B780.69%
2016-12-31S$25.01 M-15%
2015-12-31S$29.42 M60.96%
2014-12-31S$18.28 M-47.27%
2013-12-31S$34.67 M

Total debt for similar companies or competitors

Company Total debt differencediff. Country
N/AN/A๐Ÿ‡บ๐Ÿ‡ธ USA
S$0.35 B-75.28%๐Ÿ‡บ๐Ÿ‡ธ USA